BMS says Phase III trials for Opdivo show improved overall survival in lung cancer
May 19, 2016Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo
Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …
Bayer makes bid for Monsanto
May 19, 2016Manufacturing and Production, Sales and Marketing Bayer, agrochemical, bid, monsanto, takeover
Bayer (ETR: BAYN) has made a move to consolidate its position in the agrochemical sector with an unsolicited takeover bid …
FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq
May 19, 2016Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq
Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
Roche confirms over 200 job cuts at Irish facility
May 18, 2016Manufacturing and Production Roche, clare, clarecastle, closure, irish site, job cuts, job losses
Swiss pharmaceutical company Roche (VTX: ROG) has confirmed that 240 jobs are to go at their Irish site in Clare, …
AstraZeneca’s Lynparza fails to meet primary endpoint in Phase III gastric cancer trials
May 18, 2016Research and Development AstraZeneca, failed to meet endpoint, gastric trail, lynparza, phase III
AstraZeneca has announced that its treatment for advanced gastric cancer, Lynparza (olaparib), failed to meet the primary endpoint of overall …
Breast cancer trial stopped after meeting primary endpoint early
May 18, 2016Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib
A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
Boehringer Ingelheim says new studies underline efficacy of lung disease drug
May 18, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease
Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …
Novartis splits pharmaceuticals division into two business units
May 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division
Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …
Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma
May 18, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo
Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …
Relmada Therapeutics appoints new chief financial officer
May 17, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing chief financial officer, relmada
Michael D. Becker has been appointed the new chief financial officer at Relmada Therapeutics. Becker joined the company in 2014 …
Biogen signs $2 billion partnership deal with UPenn for gene therapies
May 17, 2016Research and Development, Sales and Marketing Biogen, collaboration, deal, gene therapy, research
Biogen (Nasdaq: BIIB) said it has signed a deal worth up to $2 billion with the University of Pennsylvania to …
Actelion granted EU approval for hypertension treatment
May 17, 2016Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension
Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …
Allergan’s chronic eye disease treatment meets endpoints in pivotal trials
May 17, 2016Manufacturing and Production, Sales and Marketing Allergan, FDA, chronic eye disease
Allergan has announced positive top line results from two pivotal late-stage trials for the first and only neurostimulation device for …
AstraZeneca says its respiratory biologic meets primary endpoint in Phase III trial
May 17, 2016Manufacturing and Production, Research and Development AstraZeneca, asthma drug, benralizumab, drug trial
UK-based AstraZeneca (LSE: AZN) on Tuesday said late stage trials for its biologic asthma drug met the primary endpoint. Chief …
Valeant announces expanded discounts for Nitropress and Isuprel
May 17, 2016Manufacturing and Production, Sales and Marketing Isuprel, Nitropress, Valeant, discounts
Valeant Pharmaceuticals (NYSE: VRX) has stepped up its public relations campaign with an announcement of expanded discounts for Nitropress (nitroprusside) …
Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge
May 17, 2016Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets
Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …
Pfizer to acquire Anacor in $5.2 billion deal
May 16, 2016Manufacturing and Production, Sales and Marketing 5.2 billion, FDA, Pfizer, acquisition, anacor, crisaborole, merger
Pfizer (NYSE: PFE) has acquired Anacor Pharmaceuticals (NASDAQ: ANAC) in a deal worth around $5.2 billion, or $99.25 per share. …
Mylan to buy Renaissance’s dermatology business for up to $1 billion
May 16, 2016Research and Development, Sales and Marketing Mylan, generics, merger and acquisition
Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …
Sanofi to replace entire Medivation board to drive sale, according to reports
May 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Medivation, Sanofi, replace board, takeover
Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it …
Weekly Movers: Teva, Midatech, Allergan…
May 16, 2016Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets
We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
